Laura E. Niklason - Jun 11, 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
President, CEO and Director, Director
Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Jun 11, 2024
Transactions value $
-$4,520,024
Form type
4
Date filed
6/13/2024, 04:48 PM
Previous filing
Jun 4, 2024
Next filing
Jun 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Sale -$2M -282K -5.43% $7.09 4.91M Jun 11, 2024 By Ayabudge LLC F1
transaction HUMA Common Stock Sale -$538K -76.6K -1.56% $7.02 4.83M Jun 11, 2024 By Ayabudge LLC F2, F3
transaction HUMA Common Stock Sale -$1.98M -272K -5.62% $7.30 4.56M Jun 12, 2024 By Ayabudge LLC F2, F4
holding HUMA Common Stock 241K Jun 11, 2024 Direct
holding HUMA Common Stock 1.15M Jun 11, 2024 By The Niklason Living Trust
holding HUMA Common Stock 510K Jun 11, 2024 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold in a private transaction to a trust controlled by family members of the Reporting Person. Said family members do not share the same household as the Reporting Person.
F2 The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
F3 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.00 to $7.115. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.545. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.